We are the first and only biotechnology company in Lithuania manufacturing advanced therapy medicinal products (ATMPs) individually for each patient. We develop our products using patients’ own tissues and cells in the manufacturing process, and by addressing the specific needs of each person. All our processes are carried out using the most advanced technologies for […]
In mid-2015, we established our laboratory for the manufacture of ATMPs, in accordance with Good Manufacturing Practice requirements and procedures for the production of ATMPs approved by the Ministry of Health. We currently use this laboratory to produce ATMPs such as a dendritic cell vaccine for use in cancer immunotherapy and a T-cell product for […]Read more
One of our services is the preparation of stromal vascular fraction cells (SVF) from adipose tissue for use in therapy. SVF can be used to help regenerate articular cartilage tissues, restore damaged or sagging skin, or can participate in new vascular network formation in patients with critical limb ischemia. The tissue bank collects, processes, stores […]Read more
In April 2016, we opened the doors of a scientific laboratory that now operates 24 hours a day. We conduct research into methods of cancer immunotherapy using cell-derived products in collaboration with our partners from Lithuania, Austria, Estonia and the Czech Republic. Our research partners include National Cancer Institute, Joint Life Sciences Centre, State […]Read more
Cancer immunotherapy using a dendritic cell vaccine (DCV) is a supplementary cancer treatment method, created individually for each patient.
Read more
Individually for each patient developed stem cell preparation, which restore the functions of many types of damaged tissue.
Read more
T-cell preparation allow a doctor to stop the immune system’s response to the nerve-covering insulating layer of myelin.
Read more
06/25/2018
We recognize that the information we collect from patients and doctors is often of a highly sensitive nature. Because of that, the security of their data and the transparency of its management is on the highest importance for us and as an organization. We have adopted the highest privacy compliance standards relevant to ensure personal […]
Read more
03/09/2018
Our team’s researchers published a scientific article for Spandidos Publications journal Oncology Letters on the effectiveness of anti-cancer vaccines in the treatment of metastatic disease in murine models.
Read more
09/20/2017
Presently, “Froceth”, JSC and the National Institute of Cancer are implementing the project “Medical products modulating the advanced therapy immune system for the treatment of cancer” that is co-funded with the support of the European Fund of Regional Development provided according to the Programme of Investment Actions of the EU-Funds 2014–2020.
Read more
